Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPFS-1169 subcutaneous dosing in Parkinson's disease
2006-000361-11Phase 2Completed
- Sponsor
- Fujimoto Pharmaceutical
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of benzofuranylpropylaminopentane in Parkinson's disease (PD), sponsored by Fujimoto Pharmaceutical. Primary endpoints: Minimum effective dose of FPFS-1169, Plasma concentrations associated with MED and 1 more. Started Feb 2006; status: completed.
02
Drugs
benzofuranylpropylaminopentane
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2006-000361-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000361-11.